Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (HERCREEM)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Baylor College of Medicine
Sponsor:
Collaborators:
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
Stephen Gottschalk, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00889954
First received: April 24, 2009
Last updated: February 18, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2030
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)